Comparative Pharmacology
Head-to-head clinical analysis: TZ 3 versus ZYFREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TZ 3 versus ZYFREL.
TZ-3 vs ZYFREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
ZYFREL is a selective serotonin reuptake inhibitor (SSRI) that inhibits serotonin reuptake at the presynaptic terminal, increasing serotonergic neurotransmission in the CNS.
100 mg orally twice daily
500 mg orally every 12 hours.
None Documented
None Documented
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
12-15 hours, terminal elimination half-life; prolonged in renal impairment (up to 30 hours), requiring dose adjustment.
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
Renal: 65% unchanged; biliary/fecal: 30% as metabolites; 5% other.
Category C
Category C
Unknown
Unknown